Hyloris Pharmaceuticals (HYL)

Last close As at 02/03/2026

EUR6.86

−0.28 (−3.92%)

Market capitalisation

EUR193m

Hyloris Pharmaceuticals is a Belgium-based specialty biopharma firm focused on reformulating and repurposing approved drugs. Its commercial-stage products includes Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic for the treatment of post-operative pain.

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Stijn Van Rompay

    CO-CEO

  • Thomas Jacobsen

    CO-CEO

  • Christophe Maréchal

    CFO